Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × HDAC-42 × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1

Interventions

Cisplatin 25 pembrolizumab 24 Carboplatin 19 Magnetic Resonance Spectroscopy 17 Gemcitabine 16 Paclitaxel 15 Drug Therapy 15 Oxaliplatin 14 Cyclophosphamide 14 Specimen Handling 12 Radiotherapy 12 Nivolumab 12 Doxorubicin 12 Capecitabine 12 atezolizumab 11 Bevacizumab 11 Docetaxel 10 Dexamethasone 10 Vincristine 9 Trastuzumab 9 Radiation 9 Pemetrexed 9 Fluorouracil 9 venetoclax 8 Prednisone 8 Ipilimumab 8 Cytarabine 8 Leucovorin 7 Etoposide 7 130-nm albumin-bound paclitaxel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡